(Q37768334)

22 August 2017

1 reference

title

New antithrombotic agents--insights from clinical trials (English)

1 reference

22 August 2017

John W Eikelboom

2

0 references

author name string

Jeremy S Paikin

series ordinal

1

1 reference

22 August 2017

John A Cairns

series ordinal

3

1 reference

22 August 2017

Jack Hirsh

series ordinal

4

1 reference

22 August 2017

language of work or name

English

0 references

publication date

29 June 2010

1 reference

Nature Reviews Cardiology

22 August 2017

1 reference

22 August 2017

7

1 reference

22 August 2017

9

1 reference

22 August 2017

498-509

1 reference

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

22 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

New oral anticoagulants in development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Triggers, targets and treatments for thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Combined antiplatelet and anticoagulant therapy: clinical benefits and risks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Low-dose aspirin for the prevention of atherothrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Clopidogrel resistance: more grist for the mill

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Cytochrome p-450 polymorphisms and response to clopidogrel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Genetic determinants of response to clopidogrel and cardiovascular events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Proton pump inhibitors and clopidogrel: putting the interaction in perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

31 March 2020

Oral anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

The disposition of prasugrel, a novel thienopyridine, in humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Prasugrel versus clopidogrel in patients with acute coronary syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

The PLATO trial: do you believe in magic?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Platelet inhibition with cangrelor in patients undergoing PCI.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Intravenous platelet blockade with cangrelor during PCI.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Cangrelor - a champion lost in translation?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Emerging anticoagulants for the treatment of venous thromboembolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Dabigatran versus warfarin in patients with atrial fibrillation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.101

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Rev

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20585330

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20585330

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20585330

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCARDIO.2010.101

1 reference

22 August 2017

1 reference